Extended Data Fig. 7: Modelling the impact of mutational signatures on the likelihood of acquired hotspot mutations.
From: Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
a, Modelled mutational profile of a BL tumor with prolonged benefit. Exome normalised reference signatures have been scaled by the observed signature exposures of the 12 BL tumors with prolonged benefit to represent a mutation probability at each trinucleotide mutation context. b, Observed mutation frequencies of KRAS/NRAS Q61H vs. all other KRAS/NRAS hotspot mutations identified in CRCs with acquired EGFR-AB resistance3,5,26. c, Modelled mutation accumulation of the permanent signatures. A varying acceleration parameter of x1, x5, x10 is applied to the tumor growth period. d, Impact of SBS17b and SBS35 on the likelihood of generating KRAS/NRAS Q61H mutations vs. all other detected KRAS/NRAS hotspot mutations.
